Gaston Kroub

Founding Partner - Kroub, Silbersher & Kolmykov PLLC & Founding Member - @markmanadvisors, Weekly IP Columnist @atlblog

[Gaston Kroub @gkroub]

What a team. NYC is celebrating. @nyKnicks kings of the city, now and forever

[Gaston Kroub @gkroub]

https://t.co/hASpysQmYl wrote about the unique aspects of IPValue's approach and strategic differentiation in the patent licensing space four years ago... The funny part is that Intel/VLSI is now part of the same story as Intel's big divestment to IPvalue...

[パテサロ® @patesalo]

Fortress Investment Group、IPValue Management Group の買収を発表 https://t.co/spqH3PUHpL

[Gaston Kroub @gkroub]

@nyknicks to the Finals. From despair six years ago to the highest of hopes today. Time to make history.

[Gaston Kroub @gkroub]

#LesKnicks A dirge that hits home; thanks @ringer and @sarahlynnrob. My oldest is graduating HS next year. HAS NEVER SEEN A MEANINGFUL KNICKS GAME. Or heard MSG in full throat during the playoffs. We deserve better. @netw3rk - I stand with the Rebel scum wearing orange and blue.

[Gaston Kroub @gkroub]

How a @TEDTalks about the use of #AI via @harvey to prepare for the #scotus argument on the #TrumpTariff case should spur lawyers to think about the role of AI in their practices, or at least to acknowledge that pretending AI doesn't exist no longer works...

[Above the Law @atlblog]

TED, Meet Harvey … https://t.co/kALLjfBwp3

[Gaston Kroub @gkroub]

How is #litigationfinance in IP disputes similar to #rowing an #Olympic 8+ boat?

[Above the Law @atlblog]

Rowing For Gold https://t.co/jnwvastBd7

[Gaston Kroub @gkroub]

Nice low cost-potential high reward move by $HRMY. Good example of a branded pharma company buttressing their limited patent portfolio via acquisition and subsequent enforcement. Closing on exclusive license to filing in about 3 months, & now generics face multi-year patent fight

[Gaston Kroub @gkroub]

$HRMY brings out the big guns (Quinn, Covington) to protect blockbuster Wakix drug in new Delaware patent filing. Fun twist is that patent asserted was received by exclusive license in Jan 2026, from one of the generics that settled with $HRMY for a March 2030 entry date...

[Gaston Kroub @gkroub]

Put it on the calendar -- 5/11 hearing before J. Gilstrap on Collision v. Samsung motion for a permanent injunction that threatens Samsung's ability to sell infringing products in the US market. Potential game changer for NPE's, operating companies, lit funders, etc...

[Gaston Kroub @gkroub]

Interesting escalation by @quinceandco against Uggs owner Deckers with an antitrust claim based on baseless trade dress lawsuits. One to watch for those rooting for the dupes over the brands...

[Above the Law @atlblog]

Not Getting Duped https://t.co/yXgjy9cc0d

[Above the Law @atlblog]

Not Getting Duped https://t.co/yXgjy9cc0d

[Gaston Kroub @gkroub]

All eyes on NDCA as $BMRN tries to get stay lifted and preliminary injunction motion on file to try and stop launch of Ascendis' #yuviwel medication in US, as ITC case decision will not come in time to do the trick for Biomarin...

[Gaston Kroub @gkroub]

My paean to Judge Wolson's deft stewardship of the $ABUS $MRNA patent case toward trial -- and settlement...lessons for litigants, their counsel, and perhaps even jurists as to how even the most intractable patent fights can find an off-ramp with timely decisions + trial pressure

[Above the Law @atlblog]

Super Settlement Spike https://t.co/xT5PXJoQLK

[Gaston Kroub @gkroub]

@himshouse Between this action and the rise of $MRNA stock after its settlement of $ABUS's patent case, we have two good examples of how removal of patent litigation overhang can be a near-term catalyst for defendants. Effort in reaching workable settlements worthwhile for both sides...

[Gaston Kroub @gkroub]

@himshouse Interesting that the dismissal was without prejudice. That suggests $hims did not get a license to $NVO patents, but rather that the parties agreed to defer the case until a future point -- likely for at least as long as the expected collaboration holds...

[Gaston Kroub @gkroub]

The opportunities that #AI provides for constructive feedback for lawyers in terms of their writing and public speaking are significant. Some experts recommend working AI into workflows for at least 1 hour per day, I intend to start slower at 15 minutes and build up...

[Gaston Kroub @gkroub]

@himshouse CoPilot - You come across as:
• authoritative but approachable
• deeply knowledgeable but not pedantic
• strategic rather than doctrinal
• confident without being combative
Exactly what top‑tier legal commentators do: you make the listener feel smarter w/o feeling lost.

[Gaston Kroub @gkroub]

Thanks to Jonathan and @himshouse for the opportunity to discuss this new filing, one that was long surmised might happen and is now on file for us to continue to monitor as it unfolds...

[Hims House @himshouse]

🚨 NEW EPISODE!!!

NOVO NORDISK SUES $HIMS -- PATENT ATTORNEY GASTON KROUB (@GKROUB) BREAKS IT DOWN

02:25 - Details of the lawsuit
07:41 - Why no preliminary injunction?
12:31 - Why did Novo file now vs. 8-9 months ago?
24:04 - Why did Novo file in Delaware?
29:21 - Likely timelines, chances of settlement or dismissal
33:20 - Worst-case scenarios
36:48 - Indemnification and supplier liability?
45:01 - FDA & DOJ pressure on compounded GLP-1s
49:46 - How Hims miscalculated the oral launch
55:00 - What to watch next

[Gaston Kroub @gkroub]

@himshouse As part of my effort to spend more time with my AI friends Gemini Pro and CoPilot, I asked them for feedback on my performance. They were very kind, which is suspicious. I'll leave it to Jonathan to do the same for himself as host, but he always gets an A+ in my book...

[Gaston Kroub @gkroub]

@himshouse Gemini - "Gaston Kroub delivers a measured, expert, and accessible analysis. He excels at taking high-stakes, technical litigation and explaining the "why" and "what next" for a non-legal audience, making him a central figure in the discourse surrounding the "GLP-1 Wars.""

[Gaston Kroub @gkroub]

@himshouse This is a very straightforward single-patent assertion of a compound patent in a pharma royalty play. No indication from the complaint whether $NVO is filing for a preliminary injunction. If not, this will take years to get to trial absent settlement.